Kodiak Sciences

View All

Diabetic Macular Edema Market | Diabetic Macular Edema Drug Portfolio
Diabetic Macular Edema Therapy Market to Witness Significant Impact in the Foreseeable Future

Diabetes is a condition in which the blood glucose (blood sugar) level is abnormally high. Glucose, which is obtained from the food consumed, is the primary source of energy in the body. However, the excess glucose level in the blood can cause health issues over time and can lead to vision disorders like Diabetic R...

Find More

Wet Age-related macular degeneration treatment market
Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market, the need of new therapies that can not only slow down the progression of the vision loss but also kill the cause behind the degeneration of the macula. The present treatment approach requires intravitreal injection of anti-VE...

Find More

Pharma News
Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter

Cumberland Pharmaceuticals has recently received approval from the US FDA for its RediTrex injection for the treatment of rheumatoid arthritis. Cumberland pharmaceuticals pharma company focusing on acquiring and commercializing prescription products has gained access to the injection from Nordic Group two years...

Find More

Johnson & Johnson
Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M

Atreca secured USD 125 Million when solid tumor trial comes into picture California based company, Atreca has bagged USD 125 million to establish its R&D activities. As the company gears up, the series C round enters, to move its lead solid tumor drug into the clinic.  Atreca has set up its credentials through V...

Find More